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Abstract
Binding of small molecules in the human leukocyte antigen (HLA) peptide-binding groove may 
result in conformational changes of bound peptide and an altered immune response, but previous 
studies have not considered a potential role for endogenous metabolites. We performed virtual 
screening of the complete Human Metabolite Database (HMDB) for docking to the multiple 
sclerosis (MS) susceptible DRB1*15:01 allele and compared the results to the closely related yet 
non-susceptible DRB1*15:03 allele; and assessed the potential impact on binding of human 
myelin basic peptide (MBP). We observed higher energy scores for metabolite binding to 
DRB1*15:01 than DRB1*15:03. Structural comparison of docked metabolites with DRB1*15:01 
and DRB1*15:03 complexed with MBP revealed that PhenylalanineMBP92 allows binding of 
metabolites in the P4 pocket of DRB1*15:01 but ValineMBP89 abrogates metabolite binding in the 
P1 pocket. We observed differences in the energy scores for binding of metabolites in the P4 
pockets of DRB1*15:01 vs. DRB1*15:03 suggesting stronger binding to DRB1*15:01. Our study 
confirmed that specific, disease-associated human metabolites bind effectively with the most 
polymorphic P4 pocket of DRB1*15:01, the primary MS susceptible allele in most populations. 
Our results suggest that endogenous human metabolites bound in specific pockets of HLA may be 
immunomodulatory and implicated in autoimmune disease.
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Introduction
Multiple Sclerosis (MS) (OMIM: 126200, MIM: 142857) is a chronic inflammatory and 
demyelinating disorder of the central nervous system (CNS). Demyelinated lesions 
throughout the CNS, involving both the white and gray matter, are responsible for 
progressive neurological deficits, although extensive heterogeneity in disability exists 
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between individuals. Genes within the human leukocyte antigen (HLA) region account for 
the largest component of the genetic risk for MS. The primary signal in the region maps to 
the DRB1 gene, and specifically to the DRB1*15:01 allele, in the class II segment of this 
locus1. This strong association is observed across multiple populations, including virtually 
all European-ancestry population examined to-date. Interestingly, DRB1*15:01 is also 
observed to be the primary predisposing allele in African American MS patients, despite the 
fact that the closely related DRB1*15:03 is much more common in this population2. 
Although DRB1*15:03 differs from DRB1*15:01 at only a single amino acid position 30 
(His >Tyr), our recent work has demonstrated that DRB1*15:03 does not play a role in 
susceptibility to MS in African Americans (Damotte et al, in prep).
The prevailing view of HLA-mediated autoimmune pathogenesis involves presentation of 
self-derived cellular proteins by HLA molecules to T cells, with resulting activation and 
immune responsiveness against the self-antigen3. In MS, several myelin-derived antigens 
have been proposed in disease pathogenesis. Both myelin basic protein (MBP) and myelin 
oligodendrocyte glycoprotein (MOG) have been shown to bind to DRB1*15:014, 5, and 
initiate an immune response against myelin. The ligands of HLA class II molecules are 
produced mainly from exogenous protein sources6. Subsequently, they are digested by 
proteases and loaded onto class II HLA molecules after internalization in a procedure 
catalyzed by an endosomal and lysosomal chaperone HLA-DM7. The processing and 
loading occurs in a devoted endosomal compartment8. The peptide-loaded HLA are 
subsequently transported to the cell surface and when recognized by CD4+ T cells, stimulate 
the Ag-specific immune response9. The peptide-binding groove of the class II HLA 
molecule consists of nine different structural pockets (P) from P1 to P9, which accommodate 
the antigen peptide side chains.
A peptide from the middle region of human MBP consisting of amino acids from position 84 
to 102 has been shown to be immunodominant for human MBP-specific T cells in individual 
carriers of the HLA-DR2 (which includes DRB1*15:01) haplotype10, 11. Further, it has been 
suggested that MBP (residue 85-99)-specific T cell clones from individuals with the DR2 
haplotype are restricted to DRB1*15:01 and the MBP (85-99) peptide was also discovered 
to bind with purified DRB1*15:0112, 13. Subsequently, two residues of MBP (85-99), valine 
(Val) and phenylalanine (Phe) at position 89 and 90, respectively, were recognized as P1 
(Val89) and P4 (Phe92) anchor residues for the binding in DRB1*15:0113. DRB1*15:01 is 
distinguished by the presence of a large, predominantly hydrophobic P4 pocket, due to the 
presence of alanine (Ala) in the polymorphic DR β-chain at amino acid position 71 
(DRβ71)14. Thus the large phenylalanine residue of the MBP peptide at position 92 in P4 
functions as a major anchor residue for HLA-DR2 binding14. In contrast, the presence of 
valine at amino acid position 86 in the DR β-chain at the base of the P1 pocket gives rise to 
a smaller pocket, obligating residence of a smaller amino acid residue14.
Recent work suggests that natural, synthetic or environmental small molecule compounds 
may efficiently occupy the pockets of HLA-DR9, 15, 16. An examination of HLA alleles 
important in type-2 diabetes mellitus (T2DM) showed that small molecules influence the 
immune response in an allele-specific way by transiently occupying a dimorphic pocket on 
the HLA-DR molecule, preventing the rapid inactivation of the heterodimer so that free 
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peptides can reach the vacant peptide binding site9, 15. These studies suggest that small 
molecule binding within the HLA peptide binding groove can result in profound alterations 
in peptide binding and potentially immune responsiveness9, 15, 16. This notion is bolstered 
by robust models of HLA mediated drug hypersensitivity demonstrating that the binding of 
small molecules in the peptide binding groove results in either changes in conformation or 
causes a register shift of the bound peptide, leading to an aberrant immune response17, 18. It 
is important to consider that accommodation of a register shift is possible only for HLA 
class II, as the binding groove of the class I HLA molecule is restricted at both ends, with 
the N and C-terminal residues of the peptide acting as anchors19. Peptides cross-presented 
by different class I alleles must bind in the same register, though not necessarily in the same 
conformation20.
Despite decades of research and development of multiple lines of disease modifying 
therapies for MS, no drugs have been successfully developed that directly inhibit the 
pathogenic T cells via inhibition of HLA-DRB1 mediated presentation of neuroantigens. 
However, recent studies suggest promise in structure-based selection and identification of 
small molecules for the alteration and inhibition of allele specific HLA class II antigen 
presentation15, 16. At the same time, it goes to follow that if exogenous molecules are 
capable of altering immune-responsiveness, naturally occurring endogenous small molecules 
may function to trigger the aberrant response observed in autoimmune diseases. Human 
metabolites are abundant, naturally occurring small molecules produced endogenously in the 
course of normal metabolic processes. Additionally, scores of small molecules have been 
shown to be derived from the human microbiome; each of the major metabolite classes have 
been observed and participate in a range of biological activities, including immune 
modulation and antibiosis21.
In this study, we hypothesized that naturally occurring small molecules may bind the MS 
susceptibility allele DRB1*15:01, resulting in conformational changes or causing a register 
shift to the bound peptide and thus altering T-cell recognition and responsiveness, initiating 
an autoimmune response. We performed virtual screening of the complete Human 
Metabolite Database (HMDB) for docking to the susceptible DRB1*15:01 allele and 
compared the results to the closely related yet non-susceptible DRB1*15:03 allele; and 
assessed the potential impact on binding of human myelin basic peptide (MBP).
Results
Structural analysis and identification of pockets
Structural analysis of the MBP bound DRB1*15:01 and DRB1*15:03 protein structure 
shows a total of six chains: chain A, B, D and E represent the β-chain of DRB1 protein and 
chain C and F belongs to MBP (Figure 1A). The Chain A and D each consist of 180 amino 
acid residues individually, while each of chain B and E contains 191 amino acid residues. C 
and F chains each comprise 15 amino acid residues.
We identified a total of 9 pockets in the MBP peptide of DRB1*15:01 and DRB1*15:03 
protein structures. Val 89 and Phe 92 of MBP peptide were recognized as P1 and P4 anchor 
residues for DRB1*15:01 and DRB1*15:03 protein structures, as previously reported14. The 
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surface hydrophobicity of P1, P4 and P9 pockets are shown in Figure 1B, illustrating the 
large hydrophobic P4 pocket that is specific to DRB1*1501.
Docking of human metabolites as MHC Loading Enhancers for DRB1 alleles
We provided energy score, van der Waals component, electrostatic component, polar 
solvation component and apolar solvation component, molecular weight, partition 
coefficient (xlogP), molecular charge, heavy atoms, polar contacts, nonpolar contacts, and 
number of conformations for the docked metabolites binding with DRB1*15:01 and 
DRB1*15:03 in Supplementary Tables S1, S2 and S3.
We selected the top 200 significant metabolites from the docking results in the P4 pocket for 
both DRB1*15:01 and DRB1*15:03 and ranked them on the basis of their energy score. We 
found that 78 and 81 metabolites bind individually with DRB1*15:01 (Supplementary Table 
S1) and DRB1*15:03 (Supplementary Table S2) respectively, whereas 79 metabolites bind 
commonly to both DRB1*15:01 and DRB1*15:03 (Supplementary Table S3). We observed 
overall higher energy scores for the binding of human metabolites with DRB1*15:01 than 
DRB1*15:03 (Figure 2), suggesting generally stronger binding of metabolites to 
DRB1*15:01.
Determination of optimal pockets of the DRB1*15 alleles for binding to human metabolites
Structural comparison of the docked DRB1*15:01 and DRB1*15:03 metabolite complexes 
with DRB1*15:01 and DRB1*15:03 MBP complexes revealed that PhenylalanineMBP92 
allows the binding of metabolites in the P4 pocket of DRB1*15:01 but ValineMBP89 in the 
P1 pockets does not (Table 1). We observed differences in the energy score even for the 
binding of the same metabolites in the P4 pockets of DRB1*15:01 and DRB1*15:03 (Table 
1) or different metabolites in the P4 pockets of DRB1*15:01 and DRB1*15:03 (Table 1).
Mapping Human Metabolites on the MS phenotype
We performed data mining using metabolites we identified that bind either DRB1*15:01 or 
both DRB1*15:01 and DRB1*15:03 as input in ingenuity pathway analysis (IPA) to screen 
for human metabolites that have been previously associated with MS. We identified several 
human metabolites previously associated with MS and/or Neurodegeneration (Table 2).
Discussion
HLA-DRB1 is the primary susceptibility locus in MS1. It is likely that the crucial role of this 
molecule is mediated by presentation of peptide antigens to myelin-reactive T cells, which 
are subsequently responsible for the stimulation, proliferation, and production of pathogenic 
cytokines. Recent studies have identified small molecules that bind to the peptide-binding 
groove of DR1 and DR3, and act as a catalyst to enhance peptide loading9, 15, 16. We used an 
in silico molecular docking algorithm to virtually screen the complete Human Metabolite 
Database (HMDB) for docking to the MS predisposing DRB1*15:01 allele and compared 
the results to the closely related yet non-susceptible DRB1*15:03 allele; and evaluated the 
potential impact on binding to MBP peptide. Although small molecules have been evaluated 
with respect to antigen presentation by the HLA class II molecule (DR1 and DR3), the 
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present study is the first to screen a large database of naturally occurring human metabolites 
using a molecular docking algorithm to predict interaction with the peptide-binding groove 
of HLA-DR2.
We found considerably higher energy scores for the binding of human metabolites with 
DRB1*15:01 than DRB1*15:03 (Figure 2), suggesting stronger binding of metabolites with 
DRB1*15:01 (DR2) the primary MS associated allele. Further, our results confirm that 
phenylalanineMBP92 allows the binding of metabolites in the P4 pocket of DRB1*15:01 
(DR2) but valineMBP89 prohibits metabolite binding in P1 pockets. The most commonly 
accepted explanation for this is that the predominantly hydrophobic P4 pocket (Figure 1B), 
occupied by a phenylalanineMBP92 of the MBP peptide, is the critical feature of the DR2 
peptide-binding site and the existence of an alanine residue at the polymorphic DRβ71 
position generates the essential space for the binding of an aromatic side chain in the P4 
pocket13, 22. The presence of two aromatic residues of the P4 pocket of DR2, β26 Phe and 
β78 Tyr, of which β26 is polymorphic, also facilitate the binding of aromatic side chains by 
the P4 pocket14. The occurrence of alanine at DRβ71 is exceptional for DRB1 alleles and 
has been observed distinctively for some DR2 alleles including DRB1*15:01 and 
DRB1*15:03; other DRB1 alleles encode arginine, glutamic acid, lysine, threonine, glycine 
and serine at this position (IMGT/HLA- database version 3.27.0). DRB1*15:01 is the most 
frequently observed DR2 allele in individuals with European ancestry, who also have 
augmented risk for the development of MS. Large-scale GWAS confirms that the main 
susceptibility signal maps to the DRB1 gene in the HLA class II segment, and elucidates up 
to 10.5% of the genetic variance causal for MS susceptibility23. DRB1*15:01 has the 
greatest effect with an average odds ratios (OR) of 3.08, and all additional DRB1 
associations emerge to account for less than 2% of the residual variance23. There is 
significant variation in the distribution of DRB1*15 haplotypes across different worldwide 
populations, and these tend to correlate with the incidence of MS24. It would be interesting 
to examine whether metabolomic profiles differ similarly between world populations, and 
consider their relationship to HLA class II frequency distributions.
Previous studies reported the binding of adamantyl derivatives and plant alkaloid 
Cepharanthine in the P1 pockets of DRB1*01:01 (DR1)9, and DRB1*03:01 (DR3)16. HLA-
DR1 (HLA-DRA, DRB1*0101) and DR4 (HLA-DRA, DRB1*0401) have large P1 pockets 
due to the presence of Gly at DRβ86 position, while the arginine residue at position DRβ74 
is responsible for the larger P1 size for DR3 (HLA-DRA, DRB1*03:01); thus, the P1 
pockets may accommodate metabolite and peptide binding in DR1, DR3 and DR4. 
Meanwhile, the P1 pocket of DR2 (HLA-DRB, DRB1*15:01) is too small (Val at DRβ86) to 
accommodate small molecules such as human metabolites, whereas the greater size of the 
P4 pocket due to alanine at DRβ71 allows the binding of metabolites in the P4 pockets of 
both DRB1*15:01 and DRB1*15:03. The polymorphism at position 71 in DR2 (alanine) 
emerges to be most significant in terms of producing the accessible space for the P4 
aromatic side chain (Phe) of the MBP peptide14. The HLA-DR2 P4 pocket has an 
inclination for aromatic as well as aliphatic residues14. The P4 pocket of HLA-DR2 binding 
is detected with analogues of the MBP peptide, which contains a substitution by histidine, 
arginine, lysine, glutamine or asparagine at P4; substitution by aspartic acid is not 
tolerated13. Human metabolites appear to bind more strongly with P4 pockets of 
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DRB1*15:01 than DRB1*15:03 due to the presence of a tyrosine residue at DRβ30 position, 
the only amino acid difference between the two alleles. The tyrosine side chains have a 
neutral charge, in contrast to the positively charged side chains of histidine at position 30 of 
DRB1*15:03, which may facilitate the stronger binding of metabolites.
Numerous studies have reported the association of the P4 pocket, the most polymorphic 
pocket of the HLA-DR binding site, in augmented risk to other autoimmune diseases25-28, 
which further strengthens our observation. For example, DRB1*04:02, which has been 
associated with predisposition to pemphigus vulgaris26, 27, contrasts from the rheumatoid 
arthritis linked DRB1*04:04 allele at only three positions: DRβ67, - DRβ70, and - 
DRβ7125, 28. In DRB1*04:02, DRβ70 and -71 of the P4 pocket carry negative charges due 
to residues aspartic acid and glutamic acid respectively26, 27. In contrast, glutamine and 
lysine/arginine residues are present respectively at DRβ70 and -71 positions in the 
rheumatoid arthritis correlated DRB1*04:01 and DRB1*04:04 alleles.
The binding of human metabolites in the P4 pockets of DRB1*15:01 potentially have 
profound effects on T cell proliferation and antigen presentation. One possible scenario for 
altered T-cell recognition related to bound metabolites in DRB1*15:01 is shown in Figure 
3A. In this model the bound metabolite causes a register shift in the 9mer segment of MBP 
peptide from the normal bound position (Figure 3B). HLA class II molecules consists of an 
open binding groove, which permits higher flexibility and bound peptides may be up to 
14-20 amino acids29. The peptide-binding segment of the HLA class II molecule binds 
specific 9mer residues, which is recognized as the peptide binding register29. This 9mer 
segment is located within the binding groove of the HLA class II molecule, while the 
residues of the remaining peptide are present exterior to the groove. As the peptide occupies 
the binding groove, the anchor residues at locations P1 or P4 of the peptide register act as 
primary HLA contacts, interacting with residues in the pockets of the HLA molecule. The 
binding pockets differ among HLA molecules, which are encoded by distinctive alleles and 
are accountable for binding the peptide within the groove. The pocket residues are mainly 
obscured deep inside the binding groove. In a register shift, the MBP peptide and human 
metabolite complex may transiently occupy a pocket in the HLA peptide-binding groove and 
shift forward the next residues, sliding along the groove until the trimolecular complex of 
HLA-Peptide-Metabolite is stabilized. Alternatively, the presence of one of the high scoring 
metabolites in the P4 pocket of DRB1*15:01 may enhance the risk of MS by augmenting 
antigen loading. This possibility is supported by previous reports suggesting that a transient 
occupation of HLA-DR pocket by an organic compound stabilizes the peptide-receptive 
conformation allowing rapid antigen loading9.
Interestingly, our IPA analysis revealed that specific metabolites that bind the P4 pocket of 
DRB1*15:01, L-tryptophan, glutamic acid, D-sphingosine, sphingosine-1-phosphate, 
Cysteinyl-Glycine and NAD+ have been previously associated with MS and 
Neurodegeneration (Table 2). Similarly, the metabolomic signatures of tryptophan and 
glutamic acid have been suggested to be associated with disease severity in multiple 
sclerosis30. The sphingolipids are a class of biologically active lipids; sphingosine 1-
phosphate receptors 1 and 3 have been shown to be upregulated in multiple sclerosis 
lesions31. A homocysteinemia regulator cysteinylglycine has been linked with physiological 
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and pathological conditions in cerebro-vascular and multiple sclerosis patients32. More 
recently, human metabolites NAD(+), Myo-Inositol hexakisphosphate and glutathione have 
been correlated respectively with neurodegeneration33, regulation of morphology and 
synapse formation of cerebellar purkinje cells34, and metabolism impairment in MS35.
Recently, a study conducted in autoimmune Goodpasture disease has shown that HLA-
DR15-α3135–145 tetramer+ T cells in HLA-DR15 transgenic mice display a conventional T-
cell phenotype, which secretes pro-inflammatory cytokines and may be associated with 
augmented disease risk36. Meanwhile, HLADR1-α3135–145 tetramer+ T cells in HLA-DR1 
and HLA-DR15/DR1 transgenic mice are mainly CD4+Foxp3+ regulatory T cells (Treg 
cells) expressing tolerogenic cytokines, which is linked with disease protection36. This study 
provides a mechanistic model for the relative abundance of self-epitope specific Treg cells, 
which leads to either protection or risk of autoimmunity. The same concept may be 
applicable to the transient occupation of certain human metabolites in the P4 pocket HLA-
DRB1*15:01, altering peptide presentation and potentially resulting in a change of the 
balance of Treg vs. conventional T-cell phenotype.
Our analysis of HLA interactions with human metabolites could pave the way for similar 
investigations in clinical allo-transplantations and other autoimmune diseases, such as 
rheumatoid arthritis (RA), celiac disease (CD), systematic lupus erythmatosis (SLE), 
ankylosing spondylitis, dermatomyositis and type I diabetes mellitus (T1DM). Our approach 
might be helpful to weight or group together various HLA genes and alleles that are involved 
in susceptibility to different diseases. The findings of this study could also be useful in 
resolving the conflicts regarding the association of HLA polymorphisms with RA 
susceptibility association with anti-cyclic citrullinated peptide (ACPP) autoantibody. In 
some studies, ACCP antibodies are associated with the presence of HLA class II alleles; 
especially the DRB1 shared epitope (SE) alleles in European-ancestry RA patients37, 38, 
whereas subsequent studies have failed to replicate this association39. The identification of 
specific pathogenic metabolites in RA could help to explain some of these discrepancies. 
Similarly, Lee and colleagues have recently suggested that the genetic contribution to 
prognosis in Crohn's disease is largely independent of the contribution to disease 
susceptibility40. The detection of highly immunogenic metabolite-HLA loads in individuals 
could provide insight regarding prognosis as well as new therapeutic opportunities. Finally, 
donor-recipient matching for immunogenic metabolites that occupy specific pockets in HLA 
molecules could be a strategy employed in HLA mismatched donor-recipient pairs to 
improved transplant outcome and avoid graft rejections, providing a potential applicability 
of our study in terms of clinical allo-transplantation. Although finding the exact match of 
donor-recipient pairs for immunogenic metabolites could be challenging, donor-recipient 
pairs with low metabolite mismatch loads or without highly immunogenic metabolite 
mismatches could be considered.
In summary, we have shown that naturally occurring human metabolites bind to 
DRB1*15:01, the primary MS susceptible allele in most populations, and may potentially 
impact MS risk. An improved understanding of the kinetics of HLA binding of human 
metabolites may allow development of small molecule based immunomodulatory drugs 
antagonistic to metabolites that enhance antigen loading or alter presentation. Identification 
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of our high scoring metabolites in metabolomics studies in MS may also be informative in 
identification of suitable MS biomarkers. A limitation of our study is that we did not test the 
docked DRB1-Metabolite complex in the laboratory. This is an outstanding point of 
uncertainty and will need to be addressed in future studies to fully elucidate the role of the 
metabolites identified in silico in T-cell proliferation and antigen presentation. A structure-
based strategy could determine structural features at the peptide/HLA interface and 
recognize molecules that may stimulate or suppress TCR signaling in response to particular 
peptide antigens. The present study suggests that the combination of structure directed 
virtual screening and the notion that human metabolites targeted to certain HLA pockets 
may be immunomodulatory contains extensive applicability to adaptive immunity and 
autoimmune conditions.
Methods
Selection and Preparation of DRB1 Structure
The X-ray crystal structure for the DRB1*15:01 complex with bound peptide from human 
myelin basic protein (MBP) with a resolution of 2.6 Å was obtained from the protein data 
bank (PDB) under accession number 1BX214. We prepared the target (DRB1*15:01 and 
DRB1*15:03) and binding site residue with N-acetyl-D-glucosamine (NAG) for docking 
with human metabolites using the UCSF Chimera software package (version 1.11.2)41. 
DRB1*15:01 exon-2 sequence differs from DRB1*15:03 at amino acid position 30 from 
tyrosine (Tyr) to histidine (His). The in silico DRB1*15:03 structure was obtained from the 
known structure of DRB1*15:01 by mutating the residue Tyr30 > His30.
Virtual Screening and molecular docking of DRB1*15:01, DRB1*15:03 and Human 
Metabolites
The Human Metabolite database (HMDB) version 3.6 consists of 41,993 metabolites derived 
from various sources such as exogenous, endogenous, food, microbial, toxic and drug 
metabolites. We screened the complete HMDB library (version 3.6) for docking with 
DRB1*15:01 and DRB1*15:03. The schematic representation of the overall study design 
and molecular docking pipeline is shown in Figure 4.
Virtual screening was performed using the UCSF Chimera version 1.11.241, Clipper version 
1.6.042, and Dockblaster version 1.6.0 softwares43 as previously described41-43. UCSF 
Chimera 1.11.2 was used for the selection, visualization and preparation of target and ligand 
and the visualization and analysis of DRB1-metabolite complexes. Virtual Screening for 
DRB1*15:01 and DRB1*15:03 was conducted on a structure obtained in molecular 
dynamics (MD) simulations of the complex with a bound peptide from MBP. Clipper 1.6.0 
was used for the identification and analysis of different peptide binding pockets in 
DRB1*15:01 and DRB1*15:03.
Subsequently, we conducted independent screenings to probe each pocket from P1 to P9 of 
both DRB1*15:01 and DRB1*15:03 with HMDB (version 3.6) using Dockblaster 1.6.043, 
including the calculation of energy score, van der Waals component, electrostatic 
component, polar solvation component, molecular charge, heavy atoms, polar contacts (3.3 
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A), nonpolar contacts (3.3-4.5 A), and the number of conformations for docked DRB1 and 
metabolite complexes. The Dockblaster 1.6.0 results were used to select the top ranked 
metabolites and investigate the distribution of their scores in assessing the point beyond 
which their scores become indistinguishable. On this basis we selected metabolites from the 
docking results in each pocket and ranked them on the basis of their energy score. We used 
the following criteria to compute the energy score of docked metabolite with DRB1*15:03 
and DRB1*15:03 in kcal/mol:
Energy Score = Energy of Electrostatic interaction ES + Energy of van der Waals interaction VdW
+ Desolvation energy
Desolvation energy was calculated by combining the energy of polar solvation component 
and apolar solvation component.
Sequence alignment
In order to understand whether the human metabolites are binding in the P1 or P4 pockets, 
we performed sequence alignment of both DRB1*15:01-metabolite complex and 
DRB1*15:03-metabolite complex individually with the crystal structure of DRB1*15:01 and 
DRB1*15:03 with UCSF Chimera version 1.11.241. This comparison of each protein 
structure prior to and after the metabolite binding through sequence alignments allowed 
assessment of changes in the dynamics of DRB1*15:01 and DRB1*15:03 protein structures 
attributable to metabolite binding.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. A: Protein structure of DRB1 with bound peptide from MBP
Chain A and D have a length of 180 amino acid residues shown in blue and forest green 
respectively; the length of chain B and E is 191 amino acid residues, represented in cyan and 
yellow respectively; a shorter chain of 15 amino acid residues of MBP belongs to chain C 
and F and is shown in green and red respectively.
B: Hydrophobicity of the DRB1 protein surface. Blue patches are hydrophilic in nature 
whereas the orange patches are hydrophobic in nature.
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Figure 2. Heat Map of Binding energy Scores of Human Metabolites with either DRB1*15:01 or 
both DRB1*15:01 and DRB1*15:03
The 157 metabolites are listed on the y-axis and binding energy score of metabolites with 
DRB1*15:01 or both DRB1*15:01 and DRB1*15:03 are shown on the x-axis. Each cell 
represents the binding energy score in kcal/mol on a heatmap color scale.
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Figure 3. A: Hypothetical Model for the binding of human metabolites with DRB1*15:01 and 
DRB1*15:03 protein structures
In this model, the 9mer segments of MBP are present deep inside the binding grove of 
DRB1*15:01 and DRB1*15:03, and the remaining residues are present outside the peptide-
binding groove.
B: Three different potential registers for Human MBP85-99 binding to 
DRB1*15:01and DRB1*15:03. The 9mer residues from position 89 to 97 of MBP85-99 
peptide plays a crucial role in metabolite binding as well as T cell recognition and 
responsiveness. In the 1ST register, the red color represents the HLA contact residues of 
pockets P1, P4, P6 and P9, and the black color shows the TCR contact residues of pockets 
P2, P3, P5 and P7. The TCR contact residues allow the interaction of the DRB1-metabolite-
MBP complex with TCR for presentation to CD4+ T-cells. When a metabolite occupies the 
binding groove of the DRB1 molecule it may shift the P1 residue and all subsequent 
residues until the DRB1-metabolite complex is stabilized.
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Figure 4. Schematic representation of overall study design (left panel) and docking pipeline 
(right panel)
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Table 2
Human metabolite binding either DRB1*15:01 or both DRB1*15:01 and DRB1*15:03 
associated Phenotypes
Phenotypes Human Metabolites Pockets
Multiple Sclerosis L-tryptophan, glutamic acid, D-sphingosine, sphingosine-1-
phosphate, Cysteinyl-Glycine P4
Neurodegeneration D-sphingosine, NAD+, sphingosyl beta-glucoside P4
Progressive motor neuropathy D-sphingosine, escitalopram, glutathione, L-tryptophan, 
loperamide, sphingosine-1-phosphate
P4
Hereditary central nervous system demyelinating disease glutathione, psychosine P4
Cell death of central nervous system cells dityrosine,glutathione, NAD+ P4
Cell death of neuroglia glutathione, NAD+ P4
Apoptosis of motor neurons glutathione P4
Apoptosis of cerebellar macroneurons sphingosine-1-phosphate P4
Astrogliogenesis of neural stem cells AICAR P4
Discharge of axons AICAR P4
Invasion of nervous tissue cell lines S-adenosylmethionine P4
Mitogenesis of neurons sphingosine-1-phosphate P4
Migration of astrocytes sphingosine-1-phosphate P4
Conduction of nerves glutathione P4
Neuritogenesis of neurons sphingosine-1-phosphate P4
Prevention of Multiple Sclerosis Escitalopram P4
Proliferation of neuronal cells AICAR, hesperidin, nicotinamide adenine dinucleotide 
phosphate, sphingosine-1-phosphate, sphingosyl beta-glucoside P4
Morphology and Synapse Formation of Cerebellar Purkinje Cells Myo-Inositol hexakisphosphate P4
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